Home > News > pSivida Given a 'Speculative Buy Class A'
March 28th, 2006
pSivida Given a 'Speculative Buy Class A'
Global bio-nanotech drug delivery company, pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) is featured in a report in the March 24, 2006 issue of Bioshares, a respected Australian independent biotech investment newsletter.
Nanometrics Announces Upcoming Investor Events July 20th, 2016
Keystone Nano selected as a top scoring company by NCI investor review panel July 19th, 2016
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference July 6th, 2016
Nanometrics to Participate in the 8th Annual CEO Investor Summit: Investor Event Held Concurrently with SEMICON West 2016 in San Francisco June 22nd, 2016
Scientists find a way of acquiring graphene-like films from salts to boost nanoelectronics: Physicists use supercomputers to find a way of making 'imitation graphene' from salt July 30th, 2016
Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016
New method for making green LEDs enhances their efficiency and brightness July 30th, 2016
A new type of quantum bits July 29th, 2016